His-bundle pacing and atrioventricular nodal ablation for noncontrolled atrial arrhythmia: A technical challenge with
Corentin Chaumont1, Nathanael Auquier2, Antoine Milhem3
1Department of Cardiology, Rouen University Hospital, Rouen, France; FHU REMOD-VHF, UNIROUEN, INSERM U1096, Rouen, France.
Insights
His-bundle pacing (HBP) combined with atrioventricular nodal ablation (AVNA) is a feasible and effective treatment for uncontrolled atrial arrhythmias. This approach preserves physiological activation and improves patient outcomes, with lead placement crucial for success.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- His-bundle pacing (HBP) offers physiological ventricular activation, an advantage over traditional right ventricular pacing.
- Limited data exist on the combination of HBP and atrioventricular nodal ablation (AVNA).
Purpose of the Study:
- To evaluate the feasibility and efficacy of AVNA combined with HBP in patients with uncontrolled atrial arrhythmias.
- To provide further evidence supporting this therapeutic strategy.
Main Methods:
- Prospective study of 75 patients undergoing AVNA after HBP implantation across three hospitals (2017-2022).
- Assessment of AVNA success rates (complete block or rate control) and His-bundle (HB) lead performance.
- Evaluation of lead stability and HB capture thresholds post-procedure.
Main Results:
- Successful AVNA achieved in 77% (complete block) and 16% (rate control) of patients.
- No lead dislodgments occurred; acute HB capture threshold increases were transient in most cases.
- Significant improvements observed in New York Heart Association functional class and left ventricular ejection fraction.
Conclusions:
- AVNA combined with HBP is a feasible and clinically effective treatment for uncontrolled atrial arrhythmias.
- Optimal HB lead placement, avoiding atrial signal recording, can enhance AVNA success.
Background:
His-bundle pacing (HBP) is an appealing alternative to right ventricular pacing in patients referred for permanent ventricular pacing and atrioventricular nodal ablation (AVNA) because it preserves physiological ventricular activation. Only limited data regarding HBP combined with AVNA are available in the literature.
Objective:
The purpose of this study was to provide further evidence on the feasibility and efficacy of this therapeutic approach in patients with uncontrolled atrial arrhythmia.
Methods:
We prospectively included all patients who had undergone AVNA after HBP in 3 different hospitals between 2017 and 2022.
Results:
AVNA following HBP lead implantation was performed in 75 patients. Complete atrioventricular (AV) block was obtained in 58 patients (77%), and significant modulation of AV nodal conduction (heart rate <60 bpm) was obtained in 12 patients (16%). AVNA failure was observed in 5 patients (7%). Recording of an atrial signal by the HBP lead was more frequently observed in patients with AVNA modulation/failure than in patients with complete AV block (11/17 vs 5/58; P <.001). No lead dislodgment occurred during the AVNA procedures. Acute His-bundle (HB) capture threshold increase >1 V occurred in 11 patients (15%), with return to baseline value on day 1 in 9 patients. New York Heart Association functional class and left ventricular ejection fraction significantly improved from baseline to last follow-up (3.0 ± 0.7 vs 1.6 ± 0.5; P <.001; and 47% ± 14% vs 60% ± 9%; P <.0001, respectively).
Conclusion:
AVNA combined with HBP for noncontrolled atrial arrhythmia was feasible and clinically efficient. Implanting the HB lead on the ventricular aspect of the tricuspid annulus avoiding atrial signal recording can facilitate AVNA.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias


